ADAPY
Adaptimmune Therapeutics plc
Set alert
- YTD
- -11.54%
- 1 year
- -54.90%
- Open
- 0.0284
- Prev close
- 0.026
- Mkt cap
- 6.10M
- Vol
- 250.91K
- Avg vol
- 190.14K
- EPS
- -0.59
- P/E
- 0.00
More statistics
- Low
- 0.0205
- High
- 0.0284
News
11 months ago newsfilecorp.com
Adaptimmune Announces Changes to Board and Executive Leadership Team
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes…
1 year ago businesswire.com
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
WASHINGTON--(BUSINESS WIRE)--AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP.
1 year ago newsfilecorp.com
Adaptimmune Announces Delisting from Nasdaq
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the…
1 year ago newsfilecorp.com
Adaptimmune Reports Q2 Financial Results and Provides Business Update
Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025 Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to…
1 year ago newsfilecorp.com
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with Galapagos Purchase…
1 year ago seekingalpha.com
Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer…
1 year ago newsfilecorp.com
Adaptimmune Reports Q1 Financial Results and Provides Business Update
TECELRA ® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of…
1 year ago newsfilecorp.com
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with…
1 year ago seekingalpha.com
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial…
1 year ago newsfilecorp.com
Adaptimmune Provides Q4 and Full Year 2024 Business Update
TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA…
1 year ago newsfilecorp.com
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with…
1 year ago newsfilecorp.com
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor…
1 year ago newsfilecorp.com
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune Allo-T program to be…
1 year ago newsfilecorp.com
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down…
1 year ago newsfilecorp.com
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. -…
1 year ago seekingalpha.com
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Dan Od-Cohen - IR Adrian Rawcliffe - CEO Gavin Wood - CFO Dennis…
1 year ago newsfilecorp.com
Adaptimmune Reports Q3 2024 Financial and Business Updates
Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the…
1 year ago newsfilecorp.com
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); twenty-one partial responses (21/64) Data to be…
1 year ago newsfilecorp.com
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor…